Add demo content to test media embed displays
Closed this issue · 0 comments
Motivation
We need more comprehensive demo content with embedded media so we can test the displays of in-line media.
Is your feature request related to a problem? Please describe.
Yes, this issue is foundational work for #3439
Describe the solution you'd like
Add or adjust existing demo content to include more in-line media items (i.e. images, remote video).
Additional context
I used ChatGPT to generate a press release using the prompt: “generate a fake press release about some medical breakthough at the University of Arizona" The following is the fake press release it generated:
FOR IMMEDIATE RELEASE
University of Arizona Unveils Pioneering Treatment for Type 1 Diabetes: A Game-Changer for Patients
Tucson, AZ – July 31, 2024 – The University of Arizona has announced a groundbreaking medical breakthrough in the treatment of Type 1 diabetes, unveiling a revolutionary new therapy that holds the potential to dramatically alter the management of this chronic condition. The innovative treatment, known as Insulix-21, has demonstrated remarkable success in early clinical trials, offering new hope to millions of individuals living with Type 1 diabetes.
Developed by the University of Arizona's Center for Endocrine Research, Insulix-21 is a novel therapy that combines cutting-edge stem cell technology with advanced immunomodulation techniques. This dual-action approach not only aims to restore the body's ability to produce insulin but also prevents the autoimmune response that attacks insulin-producing cells in the pancreas.
Dr. Maria Alvarez, the principal investigator and Professor of Endocrinology at the University of Arizona, elaborated on the breakthrough: "Insulix-21 represents a significant advancement in Type 1 diabetes treatment. By leveraging stem cells to regenerate pancreatic beta cells and incorporating immunomodulatory agents to protect these cells from immune system attacks, we are addressing the root causes of the disease."
In a recent clinical trial involving 120 participants, Insulix-21 demonstrated a 65% reduction in insulin dependence and a 50% improvement in glycemic control over a 12-month period. Patients also reported enhanced quality of life and reduced incidence of diabetes-related complications.
Dr. Alvarez expressed her excitement about the potential impact of Insulix-21: "This breakthrough has the potential to not only manage Type 1 diabetes more effectively but also offer a path towards long-term remission for many patients. The early results are incredibly promising, and we are eager to continue our research and bring this transformative therapy to the wider community."
The University of Arizona is now preparing for larger-scale trials and is in discussions with leading pharmaceutical companies to accelerate the development and availability of Insulix-21. Additionally, the university has established a comprehensive support program to assist patients and families in accessing this cutting-edge therapy and managing their diabetes effectively.
This achievement highlights the University of Arizona's dedication to advancing medical research and improving patient outcomes. The Insulix-21 team is optimistic about the potential of this new treatment to make a significant difference in the lives of individuals affected by Type 1 diabetes.
For further information about Insulix-21 and ongoing research at the University of Arizona, please contact:
Press Contact:
Rachel Thompson
Director of Communications
University of Arizona
Phone: (520) 621-1986
Email: rachel.thompson@arizona.edu
Website: www.arizona.edu/insulix21
About the University of Arizona:
The University of Arizona is a leading institution in research, education, and community service. Committed to addressing global challenges through innovation and discovery, the university strives to enhance the well-being of individuals and communities worldwide.
###